‘We made 434pc on one stock – now we’re hunting for the next Ozempic’
Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want ...
HIMS Stock Slips after Catching a Downgrade from Morgan Stanley
Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...
Injectable Drug Delivery Devices Market Size Expected To Reach USD 1,217 Bn By 2034
The global injectable drug delivery devices market size is calculated at USD 565 billion in 2025 and is expected to reach around USD 1,217 billion by ...
European shares tipped to soar as US investors pile in - experts reveal the cheap stocks they would buy
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
Hims & Hers downgraded at Morgan Stanley on recent rally
Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally. Shares of ...
European stocks are set to soar as US investors pile in. Here the world's top experts reveal the dirt-cheap stocks that could make YOU a packet
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...